Browsing by Author Grigg, Andrew P.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 12 of 12
Issue DateTitleAuthor(s)Citation
2012All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Bradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Catalano, Alberto; Collins, Marnie; Dilulio, J.; et al, various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Tiley, Campbell; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineAll-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol.120, 8, 2012,pp 1570-1580
2006Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.Bradstock, Kenneth; Butler, Jason; Durrant, Simon; Fuery, Madonna; Grigg, Andrew P.; Hill, Geoffrey R.; Hutchins, Cheryl; Kennedy, Gregor; Morris, Edward S.; Morton, James; Roberts, Andrew; Szer, Jeffrey; Western Clinical School: Westmead Millennium InstituteAllogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF., Biology Of Blood And Marrow Transplantation, vol.12,(6),2006,pp 603-607
2005Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review.Hertzberg, Mark; Bashford, J.; Gill, D.; Grigg, Andrew P.; Marlton, P.; Norris, D.; Saal, R.; Seymour, John F.; Shuttleworth, P.; Waugh, M.; Western Clinical School: Medicine (Westmead)Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review., Leukemia & lymphoma, vol.46,(6),2005,pp 851-860
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phaseBradstock, Kenneth; Arthur, C.; Branford, Susan; Browett, Peter; Durrant, Simon; Gathmann, I.; Grigg, Andrew P.; Harper, A.; Hughes, T. P.; Joske, D.; Lynch, Kevin; Ma, D.; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteImatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phase, Leukemia, vol.17,(12),2003,pp 2401-2409
2015An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialBradstock, Kenneth; Arthur, Christopher; Durrant, Simon; et al, Various; Filshie, Robin; Grigg, Andrew P.; Hughes, Timothy P; Irving, Ian; Lickliter, Jason D; Szer, Jeffrey; Taylor, Kerry; Western Clinical School: Westmead Institute for Medical ResAn imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial, Leukemia & Lymphoma, vol.56, 3, 2015,pp 630-638
2004Interferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia.Arthur, Chris; Bradstock, Kenneth; Gibson, John; Browett, Peter; et, al; Grigg, Andrew P.; Hughes, T.; Januszewicz, H.; Mollee, P.; Schwarer, Anthony; Spencer, A.; Wolf, Max; Northern Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; Central Clinical School: MedicineInterferon-Alpha-2B And Oral Cytarabine Ocfosfate For Newly Diagnosed Chronic Myeloid Leukaemia., Annals of Oncology, vol.15,(12),2004,pp 1810-1815
2006PAMIDRONATE REDUCES BONE LOSS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.Bradstock, Kenneth; Ebeling, Peter R; Grigg, Andrew P.; Herrmann, Richard; Hui, C.; Reynolds, John; Schwarer, Anthony; Shuttleworth, P; Szer, J.; Western Clinical School: Westmead Millennium InstitutePAMIDRONATE REDUCES BONE LOSS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION., The Journal of Clinical Endocrinology & Metabolism (2005), vol.91,(10),2006,pp 3835-3843
2007A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioningBradstock, Kenneth; Gibson, John; Bardy, P G; Grigg, Andrew P.; Kennedy, Gregor; Koelmeyer, R L; Reynolds, John; Roberts, A W; Shuttleworth, P; Szer, J.; To, L B; Western Clinical School: Westmead Millennium Institute; Central Clinical School: MedicineA prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning, Biology Of Blood And Marrow Transplantation, vol.13,(5),2007,pp 560-567
2005Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.Gibson, John; Prosser, Ian; Bashford, J; et, al; Grigg, Andrew P.; Herrmann, R; Horvath, N; Joske, D; Lowenthal, R; McKendrick, J; Prince, Roger C; Spencer, Andrew; Central Clinical School: Medicine; MedicineProspective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation., Bone Marrow Transplantation, vol.35,(10),2005,pp 971-7
2004Real-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations.Bradstock, Kenneth; Branford, Susan; Browett, Peter; Durrant, Simon; et, al; Grigg, Andrew P.; Parkinson, Ian; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteReal-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations., Blood, vol.104,(9),2004,pp 2926-2932
2006Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders.Bradstock, Kenneth; Gottlieb, David; Hertzberg, Mark; Grigg, Andrew P.; Hoyt, R.; Huang, G.; Roberts, April; Szer, J.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders., Bone Marrow Transplantation, vol.37,(10),2006,pp 923-928
2015Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Campbell, Lynda J.; Catalano, Alberto; Collins, Marnie; Di Iulio, Juliana L.; et al, Various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineUse of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, The Lancet Haematology, vol.2, 9, 2015,pp e357-e366